CompletedPhase 2NCT01067443

Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa

Studying Leishmaniasis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Drugs for Neglected Diseases
Principal Investigator
Monique Wasunna, MD
Kenya Medical Research Institute
Intervention
Liposomal amphotericin B (AmBisome®) and sodium stibogluconate(drug)
Enrollment
151 target
Eligibility
7-60 years · All sexes
Timeline
2010 – 2011

Study locations (3)

Collaborators

Gilead Sciences · Paladin Labs Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01067443 on ClinicalTrials.gov

Other trials for Leishmaniasis

Additional recruiting or active studies for the same condition.

See all trials for Leishmaniasis →

← Back to all trials